↓ Skip to main content

Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174

Overview of attention for article published in BMC Infectious Diseases, October 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
198 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174
Published in
BMC Infectious Diseases, October 2012
DOI 10.1186/1471-2334-12-246
Pubmed ID
Authors

Nicolas Nagot, Chipepo Kankasa, Nicolas Meda, Justus Hofmeyr, Cheryl Nikodem, James K Tumwine, Charles Karamagi, Halvor Sommerfelt, Dorine Neveu, Thorkild Tylleskär, Philippe Van de Perre, for the PROMISE-PEP group

Abstract

Postnatal transmission of HIV-1 through breast milk remains an unsolved challenge in many resource-poor settings where replacement feeding is not a safe alternative. WHO now recommends breastfeeding of infants born to HIV-infected mothers until 12 months of age, with either maternal highly active antiretroviral therapy (HAART) or peri-exposure prophylaxis (PEP) in infants using nevirapine. As PEP, lamivudine showed a similar efficacy and safety as nevirapine, but with an expected lower rate of resistant HIV strains emerging in infants who fail PEP, and lower restrictions for future HIV treatment. Lopinavir/ritonavir (LPV/r) is an attractive PEP candidate with presumably higher efficacy against HIV than nevirapine or lamivudine, and a higher genetic barrier to resistance selection. It showed an acceptable safety profile for the treatment of very young HIV-infected infants. The ANRS 12174 study aims to compare the risk of HIV-1 transmission during and safety of prolonged infant PEP with LPV/r (40/10 mg twice daily if 2-4 kg and 80/20 mg twice daily if >4 kg) versus Lamivudine (7,5 mg twice daily if 2-4 kg, 25 mg twice daily if 4-8 kg and 50 mg twice daily if >8 kg) from day 7 until one week after cessation of BF (maximum 50 weeks of prophylaxis) to prevent postnatal HIV-1 acquisition between 7 days and 50 weeks of age.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 198 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 <1%
Ethiopia 1 <1%
Kenya 1 <1%
Brazil 1 <1%
United Kingdom 1 <1%
Unknown 193 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 42 21%
Researcher 35 18%
Student > Ph. D. Student 23 12%
Other 17 9%
Student > Bachelor 11 6%
Other 28 14%
Unknown 42 21%
Readers by discipline Count As %
Medicine and Dentistry 68 34%
Nursing and Health Professions 20 10%
Social Sciences 14 7%
Agricultural and Biological Sciences 8 4%
Psychology 7 4%
Other 35 18%
Unknown 46 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 February 2013.
All research outputs
#17,666,399
of 22,679,690 outputs
Outputs from BMC Infectious Diseases
#5,065
of 7,642 outputs
Outputs of similar age
#125,681
of 172,672 outputs
Outputs of similar age from BMC Infectious Diseases
#65
of 117 outputs
Altmetric has tracked 22,679,690 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,642 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,672 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 117 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.